delta-9-tetrahydrocannabinol

DRUG5 trials

Sponsors

Centre for Addiction and Mental Health, Radboud University Medical Center, Central Institute of Mental Health, Mannheim, University of Utah

Conditions

Chronic Pain, WidespreadDrug SafetyHealthyHealthy VolunteersModeling PsychosisPsychomotor Impairment

Early Phase 1

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

CompletedNCT03215940

University of UtahChronic Pain, Widespread

Start: 2018-02-01End: 2024-12-01Updated: 2025-04-13

Phase 1

Safety and Tolerability of Namisol in the Elderly

CompletedNCT01740960

Radboud University Medical CenterDrug Safety

Start: 2012-08-31End: 2012-12-31Updated: 2014-01-07

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids

CompletedNCT02487381

Central Institute of Mental Health, MannheimHealthy, Modeling Psychosis

Start: 2015-04-30End: 2015-08-31Target: 60Updated: 2015-08-17

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study

WithdrawnNCT02492074

Central Institute of Mental Health, MannheimHealthy Volunteers, Modeling Psychosis

Start: 2024-12-31End: 2025-05-31Updated: 2025-03-13

Unknown Phase

Cannabis Effects on Driving-related Skills of Young Drivers

CompletedNCT01592409

Centre for Addiction and Mental HealthPsychomotor Impairment

Start: 2012-07-31End: 2016-09-30Updated: 2019-02-11

Related Papers

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers

Frontiers in Psychiatry2020-11-1337 citations